SMARCB1 and sarcoma: Having confirmed SMARCB1 status of EPS cell models, we proceeded to screen eight EPS cell models, two SMARCB1‐null rhabdoid cell models and two normal cell lines against a custom compound library (Figure S8) consisting of 61 pre‐clinical and clinical agents selected based on relevance to biological pathways implicated in sarcoma and targets currently under investigation as therapeutic mechanisms in sarcoma (Table 3).